Oscotec: 투자판단관련주요경영사항(임상시험결과) (알츠하이머 치료 후보물질 ADELY01 임상 1a/1b상 임상시험결과보고서(CSR) 수령)

Termination of business following receipt of Phase 1a/1b clinical trial results for Alzheimer's treatment and subsequent technology transfer

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

Osstem Implant's stock price edged lower due to a management dispute and institutional selling, despite its biotech pipeline.

Following the disclosure of a management dispute lawsuit, the stock faced downward pressure as institutions sold 15,733 shares. Despite IBK Securities' positive outlook with a target price of ₩67,000, the stock closed lower due to short-term uncertainty surrounding the dispute and institutional selling.

• 09.23 ★★★★ Management dispute litigation filed following application for permission to convene general meeting of shareholders
• 09.18 ★★ [Amended] Report on Large Shareholdings (General)
• 09.17 ★★ Report on major shareholding (abbreviated)
• 09.17 ★★ Large Shareholding Report (General)
• 09.01 ★★ Large Shareholding Report (General)